Inflammatory disease Archives

News and Trends 2 Sep 2015

Arderlyx’s ‘hot potato’: Sanofi changes its mind about €175M pre-clinical research deal

Paris based Sanofi has pulled out of a €176M deal with Californian clinical stage biotech Ardelyx. A licensing deal for a program of pre-clinical candidates treating renal diseases and IBS-C, similar to Tenapanor, was revoked. In February 2015, Fresno County’s Ardelyx announced its pharma-baby, Tenapanor, had passed its stage IIB clinical trials in successfully reducing serum levels of phosphate. […]

September 2, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 6 Aug 2015

Now it’s Clear, AbbVie Has to Buy Galapagos’ Drug

Galapagos just disclosed new good results of its Phase 2B study in rheumatoid arthritis. The drug could be a lifesaver for AbbVie, which is facing patent lost of its most profitable drug Humira. Mechelen, Belgium-based Galapagos NV announced today that at week 24, patients treated with the selective JAK1 inhibitor filgotinib showed further improvement in signs […]

August 6, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 15 Jul 2015

Ferring bets on bacteriophages to treat inflammatory bowel disease

Bacteriophages have been instinctively killing bacteria for millions of years. These natural bacteria predators represent a potential alternative to antibiotics and Ferring Pharmaceuticals wants to use them against inflammatory bowel disease. The Swiss pharma joined forces with phages specialist Intralytix to manufacture these viruses for clinical purposes. Bacteriophages can be very selective when it comes […]

July 15, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 1 Jul 2015

Green light for one of the largest clinical trials in Immunotherapy

In a period, where uncountable big pharmas and biotechs are struggling to get the largest piece of the immunotherapy cake, an unexpected player has arrived. TxCell, a French biotech, received an option to extend its current phase IIb study from EU to US, a stage that lots of immunotherapy experts would like to reach. TxCell was founded fourteen years […]

July 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 May 2015

Are AbbVie and J&J already fighting to acquire Galapagos’ pipeline?

Ten years ago, Galapagos completed its initial public offering with a dual listing in Amsterdam and Brussels. Since then, Galapagos has grown, from 70 to more than 400 employees and from €70M to around €1.2Bn in market capitalization. Galapagos recently reported positive results with its JAK1 inhibitor in nearly 900 rheumatoid arthritis patients worldwide, triggering the interest […]

May 11, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 14 Mar 2015

Samsung Bioepis Submits a Biosimilar Candidate, to the European Medicines Agency

Samsung Bioepis announced their submission to the to the European Medicines Agency (EMA) for SB2, its Remicade (Infliximab) biosimilar candidate. This is the second biosimilar candidate Marketing Authorization Application (MAA) that Samsung Bioepis has submitted to the EMA. The MAA is based on results from an extensive head-to-head preclinical data package comparing SB2 to the originator, a […]

March 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 26 Feb 2015

Celltrion launches world’s first biosimilar monoclonal antibody in 12 new European markets

Celltrion Healthcare has today announced the launch of Remsima (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the UK. The treatment to the treatment of autoimmune diseases is now available in 31 countries. Remsima, developed by the South Korean company Celltrion, is the world’s first biosimilar monoclonal […]

February 26, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 26 Feb 2015

Unstoppable Ferring after the Acquisition of a novel Oral Drug Delivery Technology

Ferring Pharmaceuticals signed an agreement with South Korean CTCBIO to acquire rights to a novel oral drug delivery technology. The Swiss company is growing more and more rapidly with plenty of updates since the begining of the year. Ferring’s success in developing oral formulations for peptide drugs including the world’s first orally active peptide, desmopressin […]

February 26, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 2 Feb 2015

Will 4D Pharma be UK’s next Microbiome leader?

4D Pharma, a biopharmaceutical company focusing on significant new therapeutic areas, plan to raise €46M to continue the development of its drugs candidates and to exploit its microbiome platform MicroRx. Will 4DPharma be the next UK’s microbiome leader? This English company, founded in early 2014, has focused its current interests solely in the microbiome field and the discovery […]

February 2, 2015 - 3 minutesmins - By Lourdes Riquelme

Resources

Categories

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Inflammatory disease

Arderlyx’s ‘hot potato’: Sanofi changes its mind about €175M pre-clinical research deal

Now it’s Clear, AbbVie Has to Buy Galapagos’ Drug

Ferring bets on bacteriophages to treat inflammatory bowel disease

Green light for one of the largest clinical trials in Immunotherapy

Are AbbVie and J&J already fighting to acquire Galapagos’ pipeline?

Samsung Bioepis Submits a Biosimilar Candidate, to the European Medicines Agency

Celltrion launches world’s first biosimilar monoclonal antibody in 12 new European markets

Unstoppable Ferring after the Acquisition of a novel Oral Drug Delivery Technology

Will 4D Pharma be UK’s next Microbiome leader?

Subscribe to our newsletter to get the latest biotech news!

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!